MARKET

ONCT

ONCT

Oncternal Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.820
-0.050
-1.74%
After Hours: 2.780 -0.04 -1.42% 17:32 08/07 EDT
OPEN
2.970
PREV CLOSE
2.870
HIGH
2.970
LOW
2.670
VOLUME
83.00K
TURNOVER
--
52 WEEK HIGH
6.29
52 WEEK LOW
2.115
MARKET CAP
50.69M
P/E (TTM)
-0.6598
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ONCT stock price target is 1.500 with a high estimate of 1.500 and a low estimate of 1.500.

EPS

ONCT News

More
Oncternal Therapeutics reports Q2 results
Oncternal Therapeutics (NASDAQ:ONCT): Q2 GAAP EPS of -$0.34. Revenue of $0.62M (-7.5% Y/Y) Press Release
seekingalpha · 2d ago
Oncternal Provides Business Update and Announces Second Quarter 2020 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported second quarter 2020 financial results.
Business Wire · 2d ago
Oncternal Therapeutics to Report Second Quarter 2020 Financial Results and Provide Business Update
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2020 financial results after U.S. financial markets close on Thur
Business Wire · 07/30 12:00
Oncternal Therapeutics To Host Call On Cirmtuzumab And The Current Treatment Landscape For Mantle Cell Lymphoma Jul. 29 At 1:30 p.m. ET
Call on Wednesday, July 29th @ 1:30 p.m. Eastern Time; register here Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology
Benzinga · 07/27 12:11
Oncternal Therapeutics to Host Call on Cirmtuzumab and the Current Treatment Landscape for Mantle Cell Lymphoma
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will host a call with a key opinion leader (KOL) and members of the Oncternal management tea
Business Wire · 07/27 12:00
SAM, SOGO, INTC and EHTH among midday movers
Seeking Alpha · 07/24 16:40
Miragen Therapeutics leads healthcare gainers; Mallinckrodt and Vaxart among losers
Seeking Alpha · 07/24 15:00
AMD, SWIR among premarket gainers
Seeking Alpha · 07/24 12:24

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About ONCT

Oncternal Therapeutics, Inc., formerly GTX, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates for the treatment of cancers. Its pipeline includes cirmtuzumab, TK-216 and chimeric antigen receptor T-cell (CAR-T). Its cirmtuzumab product candidate is an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) monoclonal antibody. Cirmtuzumab is in a Phase-I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). TK216 is a small-molecule compound designed to inhibit the biological activity of E26 transformation-specific (ETS) oncoproteins. TK216 is being evaluated in combination with vincristine in a Phase-I clinical trial in patients with relapsed or refractory Ewing sarcoma. Its CAR-T product candidate targets ROR-1 and is in preclinical development as a treatment for hematologic cancers and solid tumors.
More

Webull offers kinds of Oncternal Therapeutics Inc stock information, including NASDAQ:ONCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONCT stock methods without spending real money on the virtual paper trading platform.